BR100 Increased By (0.01%)
BR30 Increased By (0.53%)
KSE100 Increased By (0.28%)
KSE30 Increased By (0.29%)
AGHA 6.35 Increased By ▲ 0.03 (0.47%)
BECO 4.39 Increased By ▲ 0.12 (2.81%)
BML 62.50 Increased By ▲ 0.05 (0.08%)
BOP 31.47 Increased By ▲ 0.24 (0.77%)
CNERGY 11.70 Increased By ▲ 0.11 (0.95%)
CSIL 5.92 Increased By ▲ 0.20 (3.5%)
FCCL 61.60 Increased By ▲ 0.06 (0.1%)
FFL 14.79 Decreased By ▼ -0.23 (-1.53%)
FNEL 1.23 No Change ▼ 0.00 (0%)
KEL 6.33 Increased By ▲ 0.07 (1.12%)
KOSM 5.90 Increased By ▲ 0.34 (6.12%)
LOTCHEM 24.79 Increased By ▲ 0.11 (0.45%)
MLCF 103.93 Decreased By ▼ -0.15 (-0.14%)
NBP 173.05 Decreased By ▼ -2.23 (-1.27%)
NCPL 51.85 Decreased By ▼ -0.92 (-1.74%)
NPL 54.19 Increased By ▲ 0.07 (0.13%)
OGDC 315.50 Increased By ▲ 2.11 (0.67%)
PACE 9.26 Increased By ▲ 0.06 (0.65%)
PAEL 35.51 Decreased By ▼ -0.29 (-0.81%)
PIBTL 13.65 Increased By ▲ 0.18 (1.34%)
PPL 226.60 Increased By ▲ 4.79 (2.16%)
PRL 80.30 Increased By ▲ 1.22 (1.54%)
PTC 46.89 Increased By ▲ 0.04 (0.09%)
SSGC 23.90 Increased By ▲ 0.03 (0.13%)
TBL 9.30 Decreased By ▼ -0.01 (-0.11%)
TELE 7.65 Increased By ▲ 0.26 (3.52%)
TPL 24.51 Decreased By ▼ -0.60 (-2.39%)
TPLP 13.04 Increased By ▲ 0.53 (4.24%)
TREET 26.05 Decreased By ▼ -0.20 (-0.76%)
TRG 53.38 Decreased By ▼ -0.06 (-0.11%)
World Print edition: 2019-11-08

US lab identifies rare new HIV strain

Published Updated

A US pharmaceutical firm has identified a new subtype of the human immunodeficiency virus (HIV), and said the finding showed that cutting edge genome sequencing is helping researchers stay ahead of mutations.

The strain, HIV-1 Group M subtype L, has been recorded in three people from blood samples taken between the 1980s and 2001, all in the Democratic Republic of Congo, Abbott laboratories told AFP on Thursday.

To classify a new subtype, three cases must be discovered independently, according to guidelines issued in 2000.

Group M is the most prevalent form of the HIV-1 virus. Subtype L is now the 10th of this group and the first to be identified since the guidelines were issued.

Antiretroviral drugs, which today can reduce the viral load of an HIV carrier to the point at which the infection is both undetectable and cannot be transmitted further, have generally performed well against a variety of subtypes, according to research. But there is also some evidence of subtype differences in drug resistance.

"Since subtype L is part of the major group of HIV, Group M, I would expect current treatments to work with it," Mary Rodgers, a principal scientist and head of the Global Viral Surveillance Program at Abbott told AFP.

Copyright Agence France-Presse, 2019

Comments

Comments are closed for this article.